Drug Trial Radar · NCT03095456
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
Last checked: Nov 19, 2026Latest source record: Feb 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
207
Actual
Start
Mar 27, 2017
Primary completion
Nov 25, 2017
Study completion Nov 25, 2017
Sponsor
- Lead sponsor
- Mylan Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Theravance Biopharma
- First posted
- Mar 29, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak Inspiratory Flow Rate.
Conditions
- Chronic Obstructive Pulmonary Disease, COPD
- Low Peak Inspiratory Flow Rate (PIFR)
Interventions
RevefenacinDrug
Revefenacin administered via nebulization.
Spiriva Handihaler®Combination product
Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
Placebo for RevefenacinDrug
Placebo administered as double blind, double dummy via nebulization.
Placebo for Spiriva Handihaler®Drug
Placebo administered as double blind, double dummy via Spiriva HandiHaler®.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Trough FEV1 on Day 29Time frame: Baseline and Day 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Research of Rock Hill
Rock Hill, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.